Invention Grant
- Patent Title: Antibody-drug-conjugate and its use for the treatment of cancer
-
Application No.: US15885220Application Date: 2018-01-31
-
Publication No.: US10912841B2Publication Date: 2021-02-09
- Inventor: Ian Rilatt , Michel Perez , Marie Lamothe
- Applicant: PIERRE FABRE MEDICAMENT
- Applicant Address: FR Boulogne-Billancourt
- Assignee: PIERRE FABRE MEDICAMENT
- Current Assignee: PIERRE FABRE MEDICAMENT
- Current Assignee Address: FR Boulogne-Billancourt
- Agency: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
- Priority: EP14305621 20140425
- Main IPC: A61K47/68
- IPC: A61K47/68
Abstract:
The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an anti-body-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said anti-body-drug-conjugate for the treatment of cancer.
Public/Granted literature
- US20180228915A1 ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER Public/Granted day:2018-08-16
Information query
IPC分类:
